This compares favorably to published prospective data form patient cohorts with various extents of tumor burden, which reported PSA response rates in the range of 57–64%, and imaging-based PR/CR in 43% after 12 weeks of RLT [14,30]. The gene discussed is KLK3; the disease is neoplasm.